USPTO 2015–2025 USPTO PatentsView US Corporation

Lexicon Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 17 granted patents across 9 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Lexicon ranks #16,951 of 49,997 tracked US assignees by granted-patent volume, with 17 patents across 9 technology areas.

#16,951
of 49,997 US assignees by volume
44th percentile
by Innovation Score (33.2/100)
9.9
avg claims per patent
-64%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R16951 · US Corporation #16,951 · 17 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MICRO 17 grants
  • MID-PACK #16,951/49,997
  • PHOTO-FINISH Lantronix
  • CPC-NARROW A61P · 9 areas
  • INNOV-THIN 33.2/100
  • CLAIMS-PAR 9.9 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DROP -64% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Lantronix, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Lexicon’s 33.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Lexicon

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Lexicon's Innovation Score is 33.2/100 (44th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Lexicon?

Each dot is one of Lexicon’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Lexicon’s own 9.9 claims/patent is at or below the 15.7 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Lexicon vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 16.916.91717.1 510152025 Granted patents (volume) Avg claims / patent Lantronix, Inc. - 17, 15.71LantronixLanxess International SA - 17, 22.82Lanxess Internati…LDR Medical, S.A.S. - 17, 17.59LDR Medical SLevita Magnetics International Corp. - 17, 15.82Levita Magnetics…Leyard Optoelectronic Co., Ltd. - 17, 13.29Leyard Optoelectr…Liebherr-components Colmar SAS - 17, 20Liebherr-componen…LIEBHERR-HAUSGERÄTE Lienz GMBH - 17, 11.59Liebherr-hausgerÄ…Liftra IP APS - 17, 12.71Liftra IP APSLexicon Pharmaceuticals, Inc. - 17, 9.94Lexicon Pharmaceu…
Lexicon vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Lexicon's grants concentrate

Lexicon Pharmaceuticals, Inc. is a focused PatentsView assignee: 9 CPC subclasses with 88.2% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (4 grants) versus a trough of 2 in 2016. By volume, Lexicon sits between Lantronix, Inc. and Liftra IP APS.

Lexicon's three-year grant acceleration

Lexicon Pharmaceuticals, Inc. shows 2 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Lexicon's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Lexicon holds 17 patents at rank #16,947, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Lexicon

By rank, the assignees closest to #16,947 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Lexicon's primary technology class.

Lexicon's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 44th percentile higher than 44% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

1.522.533.544.5 2015201620172018202120232025 2
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Lexicon Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 4 23.5%
2016 2 11.8%
2017 3 17.6%
2018 2 11.8%
2021 2 11.8%
2023 2 11.8%
2025partial year 2 11.8%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Lexicon Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

  • Lexicon Pharmaceuticals, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 88.2% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #16,951 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Lexicon Pharmaceuticals, Inc. against Lantronix, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 33.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.